Doctor explains the terrifying impact 'Godzilla of weight loss drugs' can have on the body

An injectable weight-loss medication known as the 'Godzilla' of GLP-1 medication may increase your risk of developing heart arrhythmia.

By now, you're probably familiar with Mounjaro and Wegovy, the injectable drugs which have changed the game when it comes to weight loss, and Ozempic, a drug created for Type 2 Diabetes but used off-label for weight management, but are you aware of retatrutide?

Dubbed 'triple-G' or the 'Godzilla of weight loss drugs,' retatrutide works by targeting three different hormone receptors in order to suppress appetite and increase fat burning.

Currently part of ongoing clinical trials, Retatrutide is not licensed for weight loss anywhere in the world, as research on its effectiveness continues.

Initial clinical trials have suggested the drug, manufactured by Eli Lilly, is extremely effective, with a recent study revealing that patients were able to lose around 28.3 percent of their body weight.

However, this doesn't mean that Retatrutide is without side effects, as Daniel Ghiyam (@simidoctors) explained on TikTok that results from Phase two of clinical trials suggested the drug had increased the incidence of heart arrhythmia by 14 percent when compared to the placebo group.

"There are up to 14 percent in heart arrhythmias compared to the placebo [group]," he explained in the video, dated to October 2025.

Does Retatrutide cause heart arrhythmia?

The British Heart Foundation explains that heart arrhythmias occur when your ticker is beating too fast, too slow or abnormally. While most arrhythmias are not considered dangerous, it's advised to seek medical attention if you experience heart palpitations alongside chest pain, feeling like you cannot breathe and dizziness.

Research into the safety and side effects of Retatrutide and heart arrhythmia, as well as any other cardiac side effects, is ongoing.

Bolt Pharmacy notes that the drug can lead to a dose-dependent increase in heart rate, which can lead to arrhythmia, while Oviva said the changes to heart rhythm were non-serious and more noticeable at a higher dose.

Links to heart arrhythmia wasn't the only potential side effect which Dr Ghiyam pointed out, with the doctor also noting that studies had shown other side effects such as possible bone density loss due to 'fat turnover and metabolism'.

The powerful medication also has an impact on the liver, however studies into this are ongoing.

Overall, Dr Ghiyam wasn't against the use of Retatrutide, instead cautioning his followers to wait until further research was released instead of purchasing the drug until it is approved for use.

"This is a very powerful medication that's not even out yet," he added. "Please don't go [and] order online from somewhere you don't know and start injecting this until we get more data.

The US-based doctor isn't the only person warning against using the currently unlicensed medication, with one health expert comparing it to steroid usage. "In terms of distribution and prominence in gym culture, ‘reta’ is absolutely following the pattern of steroids," Dr Luke Turnock, a performance-enhancing drugs expert at the University of Lincoln, told The Sun.

"Not only are gyms full of 'reta' users, but it is also being sold by various beauty clinics, beauty pages, and social media accounts."

Responding to the reports, a spokesperson for Eli Lilly told LADbible: "Retatrutide is an investigational, once-weekly, triple hormone receptor agonist, which activates the body's receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. It is an investigational molecule and cannot legally be sold to the public. It has not been reviewed or approved by any regulatory agency in the world. No one should consider taking anything claiming to be retatrutide outside of a Lilly-sponsored clinical trial. The company continues to warn the public about the potential dangers of fake medicines.

"Based on data from the TRIUMPH-1 study of retatrutide announced on 21 May 2026, the types of adverse events seen were generally consistent with trials of other incretin-based therapies. The most common adverse events among participants treated with retatrutide (4 mg, 9 mg, 12 mg, vs. placebo, respectively) were nausea (28.6%, 38.4% and 42.4% vs. 14.8%), diarrhea (25.2%, 34.1% and 32.0% vs. 13.5%), constipation (23.8%, 25.9% and 26.1% vs. 10.9%), vomiting (10.6%, 22.8% and 25.3% vs. 4.8%), and upper respiratory tract infection (14.2%, 12.2% and 13.1% vs. 11.6%). Incidences of dysesthesia occurred in 5.1%, 12.3%, and 12.5% of patients treated with retatrutide 4 mg, 9 mg, and 12 mg, respectively, compared with 0.9% with placebo, and incidences of urinary tract infections occurred in 7.5%, 8.8%, and 8.4% of patients treated with retatrutide 4 mg, 9 mg, and 12 mg, respectively, compared with 5.3% with placebo. Events of dysesthesia and urinary tract infections were generally mild to moderate, the majority resolved during treatment, and most participants continued taking retatrutide. Discontinuation rates due to adverse events were 4.1%, 6.9%, 11.3%, with retatrutide 4 mg, 9 mg, and 12 mg, respectively, compared with 4.9% with placebo."